Pub Date : 1900-01-01DOI: 10.3165/jjpn.cr.2019.0170
Takahiro Tominaga, S. Omori, M. Awazu
Hypertension is a known complication of non-steroidal antiinflammatory drugs (NSAIDs) in adults1). However, it has rarely been reported in children. In a retrospective study of neonates diagnosed with hypertension, indomethacin treatment for patent ductus arteriosus (PDA) was described to be associated with the development of hypertension2). It is reported that medical PDA closure is usually associated with an increase in systemic blood pressure3). The clinical course and laboratory findings of such cases, however, have not been described. We report a preterm infant who developed hypertension after the administration of indomethacin for PDA. Although our case had preceding acute kidney injury (AKI) due to indomethacin, hypertension developed after urine output started to increase. While NSAID-induced hypertension in adults has been ascribed to renal vasoconstriction and subsequent sodium retention4), the major mechanism of hypertension in our case was thought to be high after load due to increased vascular resistance, presumably induced by the inhibition of vascular prostaglandin I2 (PGI2) synthesis. Case Report
{"title":"Hypertension in a preterm after indomethacin use for patent ductus arteriosus","authors":"Takahiro Tominaga, S. Omori, M. Awazu","doi":"10.3165/jjpn.cr.2019.0170","DOIUrl":"https://doi.org/10.3165/jjpn.cr.2019.0170","url":null,"abstract":"Hypertension is a known complication of non-steroidal antiinflammatory drugs (NSAIDs) in adults1). However, it has rarely been reported in children. In a retrospective study of neonates diagnosed with hypertension, indomethacin treatment for patent ductus arteriosus (PDA) was described to be associated with the development of hypertension2). It is reported that medical PDA closure is usually associated with an increase in systemic blood pressure3). The clinical course and laboratory findings of such cases, however, have not been described. We report a preterm infant who developed hypertension after the administration of indomethacin for PDA. Although our case had preceding acute kidney injury (AKI) due to indomethacin, hypertension developed after urine output started to increase. While NSAID-induced hypertension in adults has been ascribed to renal vasoconstriction and subsequent sodium retention4), the major mechanism of hypertension in our case was thought to be high after load due to increased vascular resistance, presumably induced by the inhibition of vascular prostaglandin I2 (PGI2) synthesis. Case Report","PeriodicalId":205802,"journal":{"name":"Japanese journal of pediatric nephrology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131286787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.3165/jjpn.cr.2022.0211
M. Hirasawa, Y. Motoyoshi, S. Ono, T. Kitagawa, Shunsuke Yokota, K. Kamei, T. Yokoi, S. Furukawa, A. Yamaguchi, R. Miyata, K. Kiyohara
{"title":"A case of minimal change nephrotic syndrome with steroid glaucoma associated with angle dysgenesis","authors":"M. Hirasawa, Y. Motoyoshi, S. Ono, T. Kitagawa, Shunsuke Yokota, K. Kamei, T. Yokoi, S. Furukawa, A. Yamaguchi, R. Miyata, K. Kiyohara","doi":"10.3165/jjpn.cr.2022.0211","DOIUrl":"https://doi.org/10.3165/jjpn.cr.2022.0211","url":null,"abstract":"","PeriodicalId":205802,"journal":{"name":"Japanese journal of pediatric nephrology","volume":"144 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124610600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.3165/jjpn.rv.2021.0003
K. Kamei
Live attenuated vaccines are generally contraindicated for patients receiving immunosuppressive therapy. However, these patients are at risk of severe infection. In 21 previous reports, 400 patients under immunosuppressive therapy received 816 live attenuated vaccines. No life-threatening adverse events were observed. In our center, we conducted prospective studies of live attenuated vaccines in patients under immunosuppressive therapy for seven years. Patients who met specific immunological criteria (CD4 cell count ³ 500/mm 3 , lymphocyte blast transformation by phytohemagglutinin (PHA) ³ 101.6, and serum IgG level ³ 300 mg/dL) could receive live attenuated vaccines. The seroconversion rate for measles, rubella, varicella, and mumps was 80.0 - 95.7%, 100.0%, 59.1 - 61.9%, and 40.0 - 69.2%, respectively. In nationwide study, two-thirds of physicians wished to administer live vaccines for patients under immunosuppressants. Only two patients contracted vaccine-strain varicella in 781 immunizations. We demonstrated that live attenuated vaccines could be effective and safe even in patients with immunosuppressive agents, if their immunological parameters are within the acceptable level. We think that medical package inserts and several guidelines should be revised in the near future.
{"title":"Live attenuated vaccines for patients with oral immunosuppressive agents","authors":"K. Kamei","doi":"10.3165/jjpn.rv.2021.0003","DOIUrl":"https://doi.org/10.3165/jjpn.rv.2021.0003","url":null,"abstract":"Live attenuated vaccines are generally contraindicated for patients receiving immunosuppressive therapy. However, these patients are at risk of severe infection. In 21 previous reports, 400 patients under immunosuppressive therapy received 816 live attenuated vaccines. No life-threatening adverse events were observed. In our center, we conducted prospective studies of live attenuated vaccines in patients under immunosuppressive therapy for seven years. Patients who met specific immunological criteria (CD4 cell count ³ 500/mm 3 , lymphocyte blast transformation by phytohemagglutinin (PHA) ³ 101.6, and serum IgG level ³ 300 mg/dL) could receive live attenuated vaccines. The seroconversion rate for measles, rubella, varicella, and mumps was 80.0 - 95.7%, 100.0%, 59.1 - 61.9%, and 40.0 - 69.2%, respectively. In nationwide study, two-thirds of physicians wished to administer live vaccines for patients under immunosuppressants. Only two patients contracted vaccine-strain varicella in 781 immunizations. We demonstrated that live attenuated vaccines could be effective and safe even in patients with immunosuppressive agents, if their immunological parameters are within the acceptable level. We think that medical package inserts and several guidelines should be revised in the near future.","PeriodicalId":205802,"journal":{"name":"Japanese journal of pediatric nephrology","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126528417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：